Cargando…

Detection of AML-specific TP53 mutations in bone marrow–derived mesenchymal stromal cells cultured under hypoxia conditions

Detalles Bibliográficos
Autores principales:	Müller, Marian, Graf, Ricarda, Kashofer, Karl, Macher, Susanne, Wölfler, Albert, Zebisch, Armin, Hrzenjak, Andelko, Heitzer, Ellen, Sill, Heinz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2019
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6647597/ https://www.ncbi.nlm.nih.gov/pubmed/30941510 http://dx.doi.org/10.1007/s00277-019-03680-4

Ejemplares similares

TP53 mutated AML subclones exhibit engraftment in a humanized bone marrow ossicle mouse model
por: Pabst, Gabriel, et al.
Publicado: (2020)

Clinical implications of subclonal TP53 mutations in acute myeloid leukemia
por: Prochazka, Katharina T., et al.
Publicado: (2019)

Functional Classification of TP53 Mutations in Acute Myeloid Leukemia
por: Dutta, Sayantanee, et al.
Publicado: (2020)

Sensitive and broadly applicable residual disease detection in acute myeloid leukemia using flow cytometry‐based leukemic cell enrichment followed by mutational profiling
por: Daga, Shruti, et al.
Publicado: (2020)

Preexisting TP53 mutation in therapy-related acute myeloid leukemia
por: Schulz, Eduard, et al.
Publicado: (2014)

Comparison of acute myeloid leukemia and myelodysplastic syndromes with TP53 aberrations
por: Dutta, Sayantanee, et al.
Publicado: (2022)

High GPR56 surface expression correlates with a leukemic stem cell gene signature in CD34‐positive AML
por: Daga, Shruti, et al.
Publicado: (2019)

JAZF1/SUZ12 gene fusion in endometrial stromal sarcomas
por: Hrzenjak, Andelko
Publicado: (2016)

Therapeutic Resistance in Acute Myeloid Leukemia: The Role of Non-Coding RNAs
por: Zebisch, Armin, et al.
Publicado: (2016)

Detection of prognostically relevant mutations and translocations in myeloid sarcoma by next generation sequencing
por: Kashofer, Karl, et al.
Publicado: (2017)

p53 pathway dysfunction in AML: beyond TP53 mutations
por: Post, Sean M., et al.
Publicado: (2017)

TNFα Rescues Dendritic Cell Development in Hematopoietic Stem and Progenitor Cells Lacking C/EBPα
por: Anirudh, Subramanian, et al.
Publicado: (2020)

The Role of TP53 Mutations in the Origin and Evolution of Therapy-Related AML
por: Wong, Terrence N., et al.
Publicado: (2014)

Human gene-engineered calreticulin mutant stem cells recapitulate MPN hallmarks and identify targetable vulnerabilities
por: Foßelteder, Johannes, et al.
Publicado: (2023)

RAF Kinase Inhibitor Protein in Myeloid Leukemogenesis
por: Zebisch, Armin, et al.
Publicado: (2019)

Molecular characterization of AML‐MRC reveals TP53 mutation as an adverse prognostic factor irrespective of MRC‐defining criteria, TP53 allelic state, or TP53 variant allele frequency
por: Zhao, Davidson, et al.
Publicado: (2022)

P457: COMPLEX CARYOTYPE IS AN INDEPENDENT RISK FACTOR IN TP53-MUTATED AML
por: Rausch, Christian, et al.
Publicado: (2023)

PB1820: CD47-BLOCKER TTI-622 COMBINED WITH AZACITIDINE IN PATIENTS WITH TP53-MUTATED ACUTE MYELOID LEUKEMIA (AML) AND WITH AZACITIDINE + VENETOCLAX IN ELDERLY OR UNFIT PATIENTS WITH TP53-WILDTYPE AML
por: Daver, N., et al.
Publicado: (2022)

MicroRNAs as regulators of cisplatin-resistance in non-small cell lung carcinomas
por: Fadejeva, Irina, et al.
Publicado: (2017)

Increased Expression of Micro-RNA-23a Mediates Chemoresistance to Cytarabine in Acute Myeloid Leukemia
por: Hatzl, Stefan, et al.
Publicado: (2020)

Germline variants in the SEMA4A gene predispose to familial colorectal cancer type X
por: Schulz, Eduard, et al.
Publicado: (2014)

Panobinostat reduces hypoxia-induced cisplatin resistance of non-small cell lung carcinoma cells via HIF-1α destabilization
por: Fischer, Carina, et al.
Publicado: (2015)

EZH2 inactivation in RAS-driven myeloid neoplasms hyperactivates RAS-signaling and increases MEK inhibitor sensitivity
por: Berg, Johannes Lorenz, et al.
Publicado: (2021)

Differential profile of CDKN1A and TP53 expressions in bone marrow mesenchymal stromal cells from myeloid neoplasms
por: Lopes, Matheus Rodrigues, et al.
Publicado: (2016)

Interplay of TP53 allelic state, blast count, and complex karyotype on survival of patients with AML and MDS
por: Stengel, Anna, et al.
Publicado: (2023)

Mitigating the Risk of t-MNs Development: TP53 or Not TP53?
por: Tesio, Melania
Publicado: (2023)

The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
por: Leroy, Bernard, et al.
Publicado: (2013)

Specific subtype distribution with impact on prognosis of TP53 single-hit and double-hit events in AML and MDS
por: Stengel, Anna, et al.
Publicado: (2023)

Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates
por: Saliba, Antoine N., et al.
Publicado: (2022)

Loss of RAF kinase inhibitor protein is involved in myelomonocytic differentiation and aggravates RAS-driven myeloid leukemogenesis
por: Caraffini, Veronica, et al.
Publicado: (2020)

Inference of transcription factor binding from cell-free DNA enables tumor subtype prediction and early detection
por: Ulz, Peter, et al.
Publicado: (2019)

Publisher Correction: Inference of transcription factor binding from cell-free DNA enables tumor subtype prediction and early detection
por: Ulz, Peter, et al.
Publicado: (2020)

BRAF(V600E) promotes DC3/monocyte differentiation in human gene-engineered HSPCs and causes multisystem histiocytosis
por: Sconocchia, Tommaso, et al.
Publicado: (2023)

TP53 and TP53-associated genes are correlated with the prognosis of paediatric neuroblastoma
por: Wang, Haiwei, et al.
Publicado: (2022)

TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML
por: Weinberg, Olga K., et al.
Publicado: (2022)

On-treatment measurements of circulating tumor DNA during FOLFOX therapy in patients with colorectal cancer
por: Moser, Tina, et al.
Publicado: (2020)

Optimisation of TP53 reporters by systematic dissection of synthetic TP53 response elements
por: Trauernicht, Max, et al.
Publicado: (2023)

MUC16 and TP53 family co-regulate tumor-stromal heterogeneity in pancreatic adenocarcinoma
por: Chirravuri-Venkata, Ramakanth, et al.
Publicado: (2023)

Advanced oxidation protein products are antagonists of the HDL receptor SR-BI
por: Marsche, Gunther, et al.
Publicado: (2009)

TP53 and lacZ mutagenesis induced by 3-nitrobenzanthrone in Xpa-deficient human TP53 knock-in mouse embryo fibroblasts
por: Kucab, Jill E., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_707mitbipebh95lrpknub29qhu